Pharmaceuticals
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 30 to June 3. Resu...
2025-04-24 13:17
3528
Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...
2025-04-24 10:26
3914
Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU,China, April 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2025-04-24 07:00
4645
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeti...
2025-04-23 21:35
3299
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
HANGZHOU, China, April 22, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...
2025-04-23 15:03
2356
Samsung Biologics reports first quarter 2025 financial results
* Recorded Q1'25 consolidated revenue of KRW 1.3 trillion * Recorded Q1'25 consolidated operating profit of KRW 486.7 billion * Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service offerings INCHEON, South Korea, April 23, ...
2025-04-23 14:46
3439
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses. - ASC30 oral once-daily tablet also demonstrated a 4.5% placebo-adjusted mean body we...
2025-04-23 07:30
3514
Tianlong Showcases Innovation at Prestigious International Biomedical Forum in Kazakhstan
KARAGANDA, Kazakhstan, April 22, 2025 /PRNewswire/ -- Tianlong Science and Technology is honored to have been invited to speak at the "International Biomedical Forum: Researches and Innovations", held on April 17–18, 2025, at Karaganda Medical University inKazakhstan. In addition to presenting at...
2025-04-22 19:31
2907
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
* Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals * Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resear...
2025-04-22 16:30
4902
Docquity and AstraZeneca's Patient Support Program Educates Tens of Thousands in Thailand
* OAZisCare, digitally powered by DocquityCare, has advanced patient education and adherence for cancer care and RSV vaccines since 2024 * The collaboration helps tackle Southeast Asia's healthcare needs, with 85.7% of doctors noting immunization rates could improve with patient support (Do...
2025-04-22 11:00
5459
Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
SHANGHAI, April 22, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong...
2025-04-22 07:45
2607
BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy
CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (Nasdaq: BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 3...
2025-04-21 20:30
4311
Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)
CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study of its potential first-in-class innovative ADC ...
2025-04-21 20:10
4425
Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025
ALAMEDA, Calif. and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will be featured at the American Associatio...
2025-04-21 19:00
2676
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT), has been approved byChi...
2025-04-21 19:00
4327
DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies
SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumor antigen-specific anti...
2025-04-21 15:35
2762
Innovation and Collaboration: Advancing China's Blood Purification Industry
LIUYANG, China, April 19, 2025 /PRNewswire/ -- On April 19, 2025, the Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang,Hunan, for its annual conference, themed "Synergy and Endless Innovation." This pivotal event united ...
2025-04-19 14:30
4811
Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch
SHANGHAI, April 18, 2025 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2024 Annual Report, highlighting a bold and determined journey forward. With a specialty pharma strategy and operational efficiency, the company exceeded its commercialization targets and advanced its innovative p...
2025-04-18 22:10
4522
Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the tre...
2025-04-18 19:39
3993
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors - Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% - As the company's largest operational single-use bioreactor...
2025-04-18 14:30
5355
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 327 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 311 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 299 media titles]
2026-08-06 15:10
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 298 media titles]
2026-08-04 07:00
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 294 media titles]
2026-08-04 14:30
Most Read
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
2026-08-04 07:00
14008
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
12248
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
2026-08-04 06:00
10476
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
2026-08-04 14:30
10141